Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Precision Drilling
PDS
5
Lantheus
LNTH
US OptionsDetailed Quotes
PTCT250516P48000
- 0.00
- 0.000.00%
15min DelayClose May 9 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest48.00Strike Price0.00Turnover0.00%IV-8.52%PremiumMay 16, 2025Expiry Date3.77Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
PTC Therapeutics Newsroom
B of A Securities Upgrades PTC Therapeutics to Buy, Raises Price Target to $68
BofA Securities Upgrades PTC Therapeutics(PTCT.US) to Buy Rating, Raises Target Price to $68
PTC Therapeutics Is Maintained at Equal-Weight by Barclays
PTC Therapeutics Analyst Ratings
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Cuts Target Price to $66
Barclays Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Cuts Target Price to $42
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Cuts Target Price to $67
Baird Maintains Outperform on PTC Therapeutics, Lowers Price Target to $66
PTC Therapeutics Price Target Cut to $67.00/Share From $75.00 by JP Morgan
PTC Therapeutics Is Maintained at Overweight by JP Morgan
PTC Therapeutics Analyst Ratings
Citigroup Upgrades PTC Therapeutics to Neutral, Lowers Price Target to $40
Citi Upgrades PTC Therapeutics(PTCT.US) to Hold Rating, Cuts Target Price to $40
Scotiabank Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $55
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Cuts Target Price to $52
PTC Therapeutics: Balancing Strategic Success With Regulatory Uncertainty – A Hold Rating Analysis
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $52 to $68
Scotiabank Keeps Their Hold Rating on PTC Therapeutics (PTCT)
Hold Rating for PTC Therapeutics Amid Mixed Clinical Results and Uncertain FDA Approval Prospects
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), PTC Therapeutics (PTCT) and Larimar Therapeutics (LRMR)
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now